Page last updated: 2024-11-04

anthralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

anthracene-1,8,9-triol : An anthracenetriol that is anthracene substituted by hydroxy groups at positions 1, 8 and 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2202
CHEMBL ID46469
CHEBI ID37510
SCHEMBL ID3197
MeSH IDM0001305
PubMed CID10187
CHEMBL ID1579066
CHEBI ID2756
SCHEMBL ID3198
MeSH IDM0001305

Synonyms (201)

Synonym
AC-14842
dithranolum
unii-u8cjk0jh5m
anthralin [usp]
dithranol [inn]
4-06-00-07602 (beilstein handbook reference)
zithranol-rr
u8cjk0jh5m ,
cid_2202
bdbm50041802
nsc-629313
1,8-dihydroxy-9-anthrane
9(10h)-anthracenone,8-dihydroxy-
anthrone,8-dihydroxy-
nsc43970
nsc-43970
1,8-dihydroxy-9-anthrone
1,8-dihydroxyanthrone
DIVK1C_000021
KBIO1_000021
NCI60_004019
1,8-dihydroxy-9(10h)-anthracenone
CHEBI:37510 ,
1,8-dihydroxyanthracen-9(10h)-one
SPECTRUM_000056
anthrone, 1,8-dihydroxy-
PRESTWICK_528
BSPBIO_001868
IDI1_000021
derobin
chrysodermol
cigthranol
batidrol
anthra-derm
cignolin
lasan
dermaline
psoriacide
psoriacid-stift
NCGC00091330-01
drithocreme
einecs 214-538-0
nsc 43970
batridol
dithranolum [inn-latin]
nsc 403736
dihydroxyanthranol
ccris 628
ccris 5592
brn 2054360
drithoscalp
nsc 629313
brn 1976792
anthralin
1143-38-0
dithranol
C06831
1,8-dihydroxy-10h-anthracen-9-one
9(10h)-anthracenone, 1,8-dihydroxy-
nsc629313
nuzwlkwwnnjhpt-uhfffaoysa-
anthraline
inchi=1/c14h10o3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16h,7h2
dithranol, >=90% (hplc)
anthraderm (tn)
dithranol (inn)
D00233
anthralin (usp)
NCGC00091330-03
NCGC00091330-02
KBIOGR_000622
KBIO2_005572
KBIO2_000436
KBIOSS_000436
KBIO3_001368
KBIO2_003004
NINDS_000021
SPECTRUM4_000151
SPECTRUM3_000304
SPECTRUM2_000111
SPBIO_000122
SPECTRUM1500127
SPECTRUM5_000820
NCGC00091330-04
1,8 dihydroxy 9 anthrone
MLS001332632
MLS002415712
HMS2091K07
anthraderm
psodadrate
CHEMBL46469 ,
HMS500B03
HMS1920E07
A803172
1,8,9-trihydroxyanthracene;
NCGC00091330-05
NCGC00253941-01
NCGC00259400-01
tox21_300290
tox21_201851
nsc-755873
pharmakon1600-01500127
nsc755873
cas-1143-38-0
dtxsid7024538 ,
tox21_111115
dtxcid504538
HMS2271B09
S4590
CCG-38920
FT-0625372
EPITOPE ID:114081
AKOS015914122
anthralin [mi]
anthralin [vandf]
dithranol [mart.]
dithranol [who-dd]
dithranol [ep monograph]
dithranol [iarc]
anthralin [usp monograph]
dithranol [who-ip]
anthralin [usp-rs]
dithranol [ep impurity]
HY-B0738
SCHEMBL3197
tox21_111115_1
NCGC00091330-07
KS-5183
anthralin, dithranol
1,8-dihydroxy-9-(10h)anthracenone
1,8-dihydroxy-9(10h)-anthracenone #
W-108602
AB00051916_07
mfcd00053409
cignoline
SR-05000002011-2
sr-05000002011
anthralin, united states pharmacopeia (usp) reference standard
dithranol, european pharmacopoeia (ep) reference standard
anthralin (dithranol)
SR-05000002011-1
anthralin (dithranol), pharmaceutical secondary standard; certified reference material
SBI-0051286.P003
HMS3715H19
1,8-dihydroxy-9(10h)-anthracenone;anthralin
DB11157
Q419397
dithranol ,(s)
1,8-dihydroxy-9,10-dihydroanthracen-9-one
D97650
EN300-18537628
anthralin (usp monograph)
dithranol (ep impurity)
dithranol (ep monograph)
d05ac01
zithranol
1,8-dihydroxy-anthrone
dithranol (mart.)
dithranol (iarc)
dithranolum (inn-latin)
batridrol
anthralin (usp-rs)
ditranol
1,8,9-anthracenetriol
1,8,9-trihydroxyanthracene
MLS000028411 ,
smr000058389
1,8,9-anthratriol
CHEBI:2756 ,
anthracene-1,8,9-triol
480-22-8
wln: l c666j bq dq nq
nsc-403736
nsc403736
1,9-anthratriol
1,9-anthracenetriol
1,8-dihydroxy-9-anthranol
1,9-trihydroxyanthracene
dihydroxy-anthranol
1,8-dihydroxyanthranol
AC-12086
T1166
NCGC00247024-02
NCGC00247024-01
SR-01000743798-3
sr-01000743798
dtxcid306231
cas-480-22-8
NCGC00260440-01
tox21_202894
dtxsid7026231 ,
FT-0603410
AKOS015856460
SCHEMBL3198
CHEMBL1579066
bdbm50065
cid_10187
Q27105807
mfcd00001250
1,8,9-rihydroxyanthracene
A871993

Research Excerpts

Overview

Anthralin may have an immunomodulating effect on alopecia areata (AA) as it does in psoriasis. Anthralin 1% is an effective therapy for AA and should be continued at least 9 months.

ExcerptReferenceRelevance
"Anthralin 1% is an effective therapy for AA and should be continued at least 9 months. "( Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
Balevi, A; Özdemir, M, 2017
)
2.17
"Anthralin is a widely used topical anti-psoriatic drug that may have an immunomodulating effect on alopecia areata (AA) as it does in psoriasis. "( Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin.
Cao, L; Lui, H; Shapiro, J; Sundberg, JP; Tang, L, 2004
)
1.99
"Anthralin is a potent topical drug, inducing clearance of psoriatic plaques. "( The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria.
Birch-Machin, MA; Emmett, N; Frank, A; McGill, A; Reynolds, NJ; Turnbull, DM, 2005
)
2.08
"Anthralin is an effective topical drug for psoriasis therapy. "( Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin.
Ashton, RE; Koudsi, H; Lowe, NJ; Schaefer, H; Verschoore, M, 1984
)
3.15
"Anthralin is a most widely used compound for topical treatment of psoriasis. "( Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1.
Jessat, H; Mrowietz, U; Schwarz, A; Schwarz, T, 1997
)
3.18
"Anthralin is a safe, effective treatment for psoriasis, but its efficacy is hampered by the side-effects of irritation and staining of the uninvolved skin. "( The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration.
Friedmann, PS; Parslew, R, 1999
)
2.09
"Anthralin is a widely used, topical therapy for psoriasis. "( Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes.
Beyerle, A; Meves, A; Peus, D; Pittelkow, MR; Pott, M; Rittner, HL; Weyand, C, 2000
)
2.07
"Anthralin is an effective topical treatment for active psoriasis; however, its mechanism of action is unknown. "( Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
Ashinoff, R; Gottlieb, AB; Khandke, L; Krane, JF; Krueger, JG; Staiano-Coico, L, 1992
)
3.17
"Anthralin is a well-established and widely used compound for topical treatment of psoriasis. "( Inhibition of human monocyte functions by anthralin.
Christophers, E; Falsafi, M; Mrowietz, U; Schröder, JM, 1992
)
1.99
"Anthralin is an extremely effective, nontoxic treatment for psoriasis. "( Practical aspects of anthralin therapy.
Fiore, M, 1990
)
2.04
"Anthralin is an inhibitor of oxidative phosphorylation at concentrations found in vivo. "( On the interaction between anthralin and mitochondria: a revision.
Fuchs, J; Milbradt, R; Wölbling, RH; Zimmer, G, 1986
)
2.01

Effects

Anthralin has been a consistently effective drug for the treatment of psoriasis for more than 80 years. It has not enjoyed common use in the United States because of the unwanted side effects of irritation and staining.

ExcerptReferenceRelevance
"Anthralin has been applied in low and high concentrations with and without UV-irradiation in the treatment of psoriasis (Schauder & Mahrle, 1982a,b). "( Anthralin inflammation versus UV-erythema in psoriatics.
Mahrle, G; Schauder, S, 1983
)
3.15
"Anthralin has been a consistently effective drug for the treatment of psoriasis for more than 80 years, but has not enjoyed common use in the United States because of the unwanted side effects of irritation and staining. "( Old wine in new bottles: the revival of anthralin.
Harris, DR, 1998
)
2.01

Actions

Anthralin was found to inhibit the enzyme activity in a dose-dependent manner but not to display any stimulatory effects.

ExcerptReferenceRelevance
"Anthralin-caused increase in cyclooxygenase activity was detected at 6 hr after the addition of anthralin."( Anthralin, a non-TPA type tumor promoter, synergistically enhances phorbol ester-caused prostaglandin E2 release from primary cultured mouse epidermal cells.
Aizu, E; Kato, R; Yamamoto, S, 1992
)
2.45
"Anthralin was found to inhibit the enzyme activity in a dose-dependent manner but not to display any stimulatory effects."( The antipsoriatic drug, anthralin, inhibits protein kinase C--implications for its mechanism of action.
Fruchtmann, R; Hegemann, L; Mahrle, G; Müller-Peddinghaus, R; van Rooijen, LA, 1992
)
1.31

Treatment

Anthralin-UVA treatment model for antioxidant activity in the epidermis is a potentially feasible method to estimate activity of antioxidants in the body. Anthralin treatment did not induce cell-cycle-specific growth arrest as assessed by flow-cytometric analysis.

ExcerptReferenceRelevance
"The anthralin-UVA treatment model for antioxidant activity in the epidermis is a potentially feasible method to estimate activity of antioxidants in the body."( An EPR method for estimating activity of antioxidants in mouse skin using an anthralin-derived radical model.
Kawai, S; Matsumoto, K; Utsumi, H, 2010
)
1.07
"Anthralin treatment did not induce cell-cycle-specific growth arrest as assessed by flow-cytometric analysis of acridine-orange-stained keratinocytes."( Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
Ashinoff, R; Gottlieb, AB; Khandke, L; Krane, JF; Krueger, JG; Staiano-Coico, L, 1992
)
2.45
"Anthralin ("minute treatment"), tar, corticosteroids, photochemotherapy and retinoids are the most frequently used treatments, some by the general practitioner, other by the dermatologist."( [Ambulatory treatment of psoriasis].
Tapernoux, B, 1989
)
1

Toxicity

ExcerptReferenceRelevance
"Primary cultured rat epidermal keratinocytes were used as an experimental model to detect oxidant-mediated adverse effects of dithranol (anthralin), a widely used antipsoriasis drug with tumor-promoting and skin-irritating properties."( Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. I. The role of reactive oxygen species.
Acosta, D; Hsieh, GC, 1991
)
0.48
" Safety was determined from reports of adverse events and blood chemistry analysis."( The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol.
Hutchinson, PE; Marks, R; White, J, 2000
)
0.31
" Our purpose is to compare the rates of adverse events associated with different topical psoriasis treatments."( A systematic review of adverse effects associated with topical treatments for psoriasis.
Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003
)
0.32
" We found UVB and dithranol treatment to be effective and safe in moderate to severe psoriasis."( Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis.
De Boo, T; Gerritsen, MJ; Prins, M; Sminkels, OQ; Van De Kerkhof, PC; Van Der Valk, PG; Van Der Wilt, GJ; Veeniiuis, RT,
)
0.13
" The antiproliferative, anti-inflammatory and toxic effects of Nap-DTH were assessed, at the cellular level, using various in vitro methods."( Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on HaCaT cells.
Heard, CM; Lau, WM; Ng, KW; White, AW, 2011
)
0.37
" Safety was assessed by recording adverse events."( The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine.
Beulens, CA; de Jong, EM; Oostveen, AM; Seyger, MM; van de Kerkhof, PC, 2014
)
0.4
" The only adverse event reported was irritation of the skin."( The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine.
Beulens, CA; de Jong, EM; Oostveen, AM; Seyger, MM; van de Kerkhof, PC, 2014
)
0.4
" The most common complication was bullae (25%), and the least frequent side effect was generalized pruritus (3."( Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Abedini, R; Ghandi, N; Mirshamsi, A; Nasimi, M; Seirafi, H; Shakoei, S, 2019
)
0.82
" These methods are considered safe in children."( A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based
Behrangi, E; Dodangeh, M; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A; Seirafianpour, F, 2022
)
0.94

Compound-Compound Interactions

Low-dose narrow-band UVB phototherapy combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol.

ExcerptReferenceRelevance
"5-1% dithranol in white petrolatum were used in combination with UVB."( Ditrastick combined with UVB. An alternative regimen for plaque psoriasis.
Brandt, H, 1989
)
0.28
" We used low-dose narrow-band UVB phototherapy, combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol for treatment of psoriatic patients in our day care centre."( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.
Bos, JD; de Rie, MA; Out, TA, 1998
)
0.52
" Subsequently, this low-dose irradiation regimen was used in combination with topical medication in 26 psoriatic patients."( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.
Bos, JD; de Rie, MA; Out, TA, 1998
)
0.3
"Our data indicate that low-dose narrow-band UVB can be used successfully, in combination with topical treatment, in a day care setting to treat psoriatic patients."( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.
Bos, JD; de Rie, MA; Out, TA, 1998
)
0.3
"Treatment of psoriasis with dithranol as monotherapy or dithranol in combination with UVB phototherapy is an effective and safe approach for the management of psoriasis."( Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis.
Boezeman, JB; Elbers, ME; Gerritsen, MJ; van de Kerkhof, PC,
)
0.13
" The efficacy of whole body exposure to narrow-band UVB (311 nm) combined with dithranol in psoriasis has not been evaluated to date."( Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study.
Böni, R; Burg, G; Carrozza, P; Häusermann, P; Nestle, FO, 2000
)
0.31
"In patients with widespread psoriasis, treatment with narrow-band UVB (311 nm) combined with dithranol is safe and effective, allowing reduction of the cumulative irradiation dose."( Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study.
Böni, R; Burg, G; Carrozza, P; Häusermann, P; Nestle, FO, 2000
)
0.31
"To compare the clinical efficacy, in a half-side manner, of UVB (311 nm) in combination with either calcitriol or dithranol."( Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis.
Bröcker, EB; Eggert, AA; Goebeler, M; Hofmann, UB, 2003
)
0.32
" A clinical comparison of UVB (311 nm) in combination with either calcitriol or dithranol revealed no significant therapeutic differences between the regimens."( Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis.
Bröcker, EB; Eggert, AA; Goebeler, M; Hofmann, UB, 2003
)
0.32
"Combination of narrow-band UVB (311 nm) therapy with calcitriol is equally effective as the combination with dithranol for the treatment of psoriasis."( Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis.
Bröcker, EB; Eggert, AA; Goebeler, M; Hofmann, UB, 2003
)
0.32
"Treatment of plaque-type psoriasis with laser in combination with topical treatment is a safe and effective therapy."( Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol.
Bodendorf, MO; Grunewald, S; Kauer, F; Paasch, U; Rogalski, C; Schetschorke, M; Simon, JC, 2012
)
0.38
"To treat alopecia areata unresponsive to topical immunotherapy alone, topical immunotherapy in combination with anthralin is worth a try."( Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Hino, H; Kagami, S; Kishi, Y, 2020
)
1.03
"A prospective randomized clinical trial was conducted on 50 patients with Alopecia areata who received DPCP alone (group D) or in combination with anthralin (group D/A)."( A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
Abedini, R; Aryanian, Z; Daneshmand, R; Ghandi, N; Hatami, P; Nasimi, M; Vance, TM, 2021
)
1.06

Bioavailability

ExcerptReferenceRelevance
" These studies demonstrate that PPI can be exploited to improve the topical bioavailability of the molecules in a controlled pattern."( Hyperbranched dendritic nano-carriers for topical delivery of dithranol.
Agrawal, U; Gupta, U; Jain, NK; Mehra, NK, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Anthralin erythema and oedema increased with dose but the dose-response curves showed no significant difference with or without terfenadine.

ExcerptRelevanceReference
" In metaphase analysis of in vitro treated human lymphocytes, dithranol, 10-acetyl dithranol and 10-propionyl dithranol produced significant increases in the number of chromosome and chromatid gaps but without a clear dose-response relationship, and without inducing significant breaks."( Toxicological studies with dithranol and its 10-acyl analogues.
Kirkland, D; Männistö, PT; Tikkanen, L; Viluksela, M, 1986
)
0.27
"The inflammatory dose-response to anthralin was measured in human skin 24 h after pretreatment with topical corticosteroids and anthralin, and 48 h after removal of the stratum corneum with adhesive tape."( Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
Lawrence, CM; Shuster, S, 1985
)
0.92
" Dose-response data for dilutions of clobetasol propionate and betamethasone 17-valerate showed progressive diminution of both local and systemic effects with decreasing concentrations."( The effect on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis.
Clement, M; du Vivier, A; Hehir, M; Phillips, H, 1983
)
0.27
"Anthralin erythema dose-response curves were drawn for thirty adult patients of various skin types who had chronic plaque psoriasis."( Relationship between skin type and erythemal response to anthralin.
Greaves, MW; Maurice, PD, 1983
)
1.95
" Within a few days the dosage was increased to 3% dithranol and the application time to 20 min if possible."( [Experiences with high-dosage short-term dithranol therapy of psoriasis].
Göring, HD; Voss, M, 1984
)
0.27
"The inflammatory dose-response to topical anthralin and whole skin aryl hydrocarbon hydroxylase (AHH) activity were measured before and 24 h after application of a coal tar solution to the uninvolved skin of patients with psoriasis."( Effect of coal tar on cutaneous aryl hydrocarbon hydroxylase induction and anthralin irritancy.
Finnen, MJ; Lawrence, CM; Shuster, S, 1984
)
0.76
" However, dose-response studies with respect to DMBA in the two strains in two-stage carcinogenesis suggested that metabolic activation of DMBA to the active carcinogen was not limiting in the resistant strain."( Two-stage skin carcinogenesis in sensitive and resistant mouse strains.
Ashman, LK; Cook, MG; Kotlarski, I; Murray, AW, 1982
)
0.26
" Within a few days the dosage was increased up to 3% anthralin and the application time up to 20 minutes if possible."( [A very promising treatment method in psoriasis. Short-term anthralin therapy].
Kunze, J; Petres, J, 1981
)
0.75
" Responses to epicutaneous challenge with a series of concentrations of DNCB were measured as volumes calculated from diameter and thickness and the various groups were compared by the differences in the log dose-response curves."( Impaired contact hypersensitivity in untreated psoriasis and the effects of photochemotherapy and dithranol/UV-B.
Friedmann, PS; Moss, C; Shuster, S, 1981
)
0.26
" This study illustrates that PGE2 dose-response curves may reflect different mechanisms of action that may be intimately associated with skin irritant and tumour promoting activity."( Comparison of tumour promoter-induced prostaglandin E2 release in human and rat keratinocytes.
Benford, DJ; Lawrence, JN, 1995
)
0.29
"Freshly excised, full-thickness porcine ear skin was dosed with saturated solutions of the compounds."( Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining.
Heard, CM; Lau, WM; White, AW, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antipsoriaticA drug used to treat psoriasis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
anthracenetriolA polyphenol that is anthracene carrying three hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (79)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency18.31740.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain A, CruzipainTrypanosoma cruziPotency4.36880.002014.677939.8107AID1476
15-lipoxygenase, partialHomo sapiens (human)Potency3.16230.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency15.37933.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.71010.006038.004119,952.5996AID1159521
USP1 protein, partialHomo sapiens (human)Potency46.79590.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency67.75340.000221.22318,912.5098AID1259243
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.38470.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency38.94620.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency36.50700.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.09550.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency0.07940.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency2.11320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.01930.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency13.33220.001019.414170.9645AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.55060.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency15.71910.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency14.856319.739145.978464.9432AID1159509
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency69.62190.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency35.48130.010039.53711,122.0200AID1479
importin subunit beta-1 isoform 1Homo sapiens (human)Potency3.26435.804836.130665.1308AID540253
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency25.11890.65619.452025.1189AID927
snurportin-1Homo sapiens (human)Potency3.26435.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency3.26435.804816.996225.9290AID540253
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency1.41250.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency22.38720.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency1.42190.251215.843239.8107AID504327
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency25.50800.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency29.84930.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency1.99531.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency25.11891.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency71.32740.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency12.36153.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency19.59160.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency19.59160.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency37.65050.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.00010.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency6.95140.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency36.29610.001530.607315,848.9004AID1224841; AID1224848; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency77.35030.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.21670.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency14.71600.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency13.869819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency4.92120.057821.109761.2679AID1159526
heat shock protein beta-1Homo sapiens (human)Potency24.66440.042027.378961.6448AID743210
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency3.54810.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency14.58100.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
microphthalmia-associated transcription factor isoform 9Homo sapiens (human)IC50 (µMol)4.39920.00481.37104.9290AID1259371; AID1259373; AID1259375
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)100.00000.270026.3638100.0000AID504719
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)7.00000.00011.68479.3200AID7197
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)32.00000.18001.75824.0000AID160507; AID160508; AID54297; AID6881; AID6882
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)IC50 (µMol)151.20000.10003.38006.6000AID1455609; AID1455622; AID1742983
Mcl-1Homo sapiens (human)IC50 (µMol)2.39210.40007.134454.0000AID1417
DNA (cytosine-5)-methyltransferase 1 isoform bHomo sapiens (human)IC50 (µMol)1.90001.29008.755541.0000AID602386
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)16.90000.270026.3638100.0000AID504719
3-oxo-5-alpha-steroid 4-dehydrogenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)19.90000.00427.468021.1000AID2073
3-oxo-5-alpha-steroid 4-dehydrogenase 2Rattus norvegicus (Norway rat)IC50 (µMol)19.90000.00037.329421.1000AID2073
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (255)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (88)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (188)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID688879Growth inhibition of human NHEK cells after 72 hrs by neutral red uptake assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID85491Induction of Keratinocyte Differentiation in cross-linked envelope assay at 5 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID1605075-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID688876Inhibition of phosphorylated EGFR dimerization in HPV-16 transformed human CCD-1106 cells at 348.8 uM after 30 mins by densitometric analysis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1363742Inhibition of bacterial NDM1 at 200 uM using chromacef as substrate preincubated for 10 mins followed by substrate addition2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID688903Cytotoxicity against human HaCaT cells assessed as LDH release after 6 hrs by CYTOX-96 assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID233181Reducing activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH) with equimolar compound1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID494205Antiproliferative activity against human HaCaT cells assessed as LDH release at 2 uM after 48 hrs by phase contrast microscopy2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 1. Synthesis and antiproliferative activity of simple N-unsubstituted 10H-acridin-9-ones against human keratinocyte growth.
AID85617Activity of LDH release in HaCaT cells after treatment with 2 uM concentration of the compound2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID333171Inhibition of TPA-induced ROS production in human neutrophils at 5 uM by chemiluminescence2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID25770Reducing activity against 2,2-diphenyl-1-picrylhydrazyl1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID1257025Antiproliferative activity against human HaCaT cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1257018Antioxidant activity assessed as increase of DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 60 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1605085-LO inhibitory activity, measured by production of 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 (LTB4) in bovine polymorphonuclear leukocytes1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids.
AID379834Antioxidant activity assessed as DPPH radical scavenging activity at equimolar amount of compound1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID85496Deoxyribose degradation measured as hydroxyl radical generation in HaCaT cell at 75 uM expressed as malondialdehyde released2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID688902Cytotoxicity against human HaCaT cells assessed as LDH release after 24 hrs by CYTOX-96 assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID104137Inhibition of 2,2'-azobis(2-aminopropane)hydrochloride (AAPH) induced lipid peroxidation in bovine brain phospholipid liposomes1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID232854Deoxyribose degradation activity was measured as hydroxyl radical formation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID1257029Cytotoxicity against human HaCaT cells assessed as cell survival at 1 uM after 48 hrs by MTT assay (Rvb = 97.50 +/- 0.71%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID536638Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM after 4 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis and biological evaluation of novel 10-benzyl-substituted 4,5-dichloro-10H-anthracen-9-ones as inhibitors of keratinocyte hyperproliferation.
AID1257024Acute toxicity in Fisher 344 rat up to 0.1 mmol/kg, ip2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID379833Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID380857Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID6881Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID1455609Inhibition of human recombinant N-terminal Strep2-tagged SIRT5 expressed in Escherichia coli BL21 (DE3) using Abz-GVLK(glutaryl)AY(NO2)GV-NH2 as substrate in presence of NAD+ by fluorescence assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Potent and Selective Inhibitors of Human Sirtuin 5.
AID85498Antiproliferative activity against growth of HaCaT cell was determined2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID1257031Cytotoxicity against human HaCaT cells assessed as cell survival at 100 uM after 48 hrs by MTT assay (Rvb = 88.07 +/- 9.81%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID85495Compound was tested for the induction of HaCaT keratinocyte differentiation at 5 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID379836Antiproliferative activity against human HaCaT cells1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 2. Antiproliferative and cytotoxic activity of gyrophoric, usnic, and diffractaic acid on human keratinocyte growth.
AID688904Cytotoxicity against HPV-16 transformed human CCD-1106 cells assessed as LDH release after 6 hrs by CYTOX-96 assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID688883Growth inhibition of human U937 cells after 72 hrs by Cell Titer 96 aqueous one solution assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID688880Growth inhibition of human THP1 cells after 72 hrs by Cell Titer 96 aqueous one solution assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID333174Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation after 24 hrs2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID333178Cytotoxicity against human HaCaT cells assessed as plasma membrane integrity damage at 5 uM2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID333177Cytotoxicity against human HaCaT cells assessed as LDH release at 5 uM after 24 hrs2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID228511Antioxidant activity, measuring Deoxyribose degradation (DD) as a measure of hydroxyl radical formation.1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids.
AID538298Antioxidant activity assessed as DPPH free radical scavenging activity2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID379832Inhibition of AAPH-induced lipid peroxidation in bovine brain phospholipid liposome1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID1148344Tumor promoting activity in ICR/Ha Swiss mouse at 80 ug administered three times a week measured for 370 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID85493Compound was tested for the induction of HaCaT keratinocyte differentiation at 1 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID380856Antiproliferative activity against human HaCaT cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID1363741Inhibition of full length human arginase 1 expressed in Escherichia coli BL21(DE3) at 200 uM using unlabeled L-arginine/L-[guanidino-14C]arginine as substrate after 5 mins by liquid scintillation counting method relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID1257035Lipophilicity, RM of the compound by RP-TLC method2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID160509Inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes using nordihydroguaiaretic acid2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID688877Growth inhibition of HPV-16 transformed human CCD-1106 cells after 72 hrs by neutral red uptake assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID85490Induction of Keratinocyte Differentiation in cross-linked envelope assay at 10 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID1363750Inhibition of human MetAP2 Mn2+ isoform at 200 uM using Met-AMC as substrate by fluorescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID688905Cytotoxicity against HPV-16 transformed human CCD-1106 cells assessed as LDH release after 24 hrs by CYTOX-96 assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID23470Partition coefficient (logP)1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
10-omega-phenylalkyl-9(10H)-anthracenones as inhibitors of keratinocyte growth with reduced membrane damaging properties.
AID228686Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID1466262Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Oxadiazole-substituted naphtho[2,3-b]thiophene-4,9-diones as potent inhibitors of keratinocyte hyperproliferation. Structure-activity relationships of the tricyclic quinone skeleton and the oxadiazole substituent.
AID688885Cytotoxicity against HPV-16 transformed human CCD-1106 cells assessed as cell viability after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID1257021Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid by UV analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID228513Deoxyribose degradation as a measure of hydroxy radical formation.1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1148369Metal chelating activity of the compound assessed as stability constant of metal chelate at 2 to 9 x 10'-5 M using Mg2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID85487Antiproliferative activity against HaCaT cells1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID688887Cytotoxicity against human HaCaT cells assessed as cell viability after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID85482Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID688736Growth inhibition of HPV-16 transformed human CCD-1106 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID6882Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1148357Metal chelating activity of the compound assessed as metal-compound complex formation using copper1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID538295Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID85485Cytotoxicity of LDH release in HaCaT cells1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids.
AID1257019Antioxidant activity assessed as DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 20 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1257027Cytotoxicity against human HaCaT cells assessed as cell survival at 0.01 uM after 48 hrs by MTT assay (Rvb = 100%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID85486Cytotoxic activity (2 uM) was measured by the amount of LDH (mU) release in HaCaT cells.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85611In vitro for antiproliferate activity against HaCaT cells1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
10-omega-phenylalkyl-9(10H)-anthracenones as inhibitors of keratinocyte growth with reduced membrane damaging properties.
AID494204Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 1. Synthesis and antiproliferative activity of simple N-unsubstituted 10H-acridin-9-ones against human keratinocyte growth.
AID1363740Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease at 500 nM using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID1455622Inhibition of SIRT5 (unknown origin) using GGQSLK[succ]FGKG as substrate after 30 mins2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Potent and Selective Inhibitors of Human Sirtuin 5.
AID19630Partition coefficient (logP)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID688884Cytotoxicity against HPV-16 transformed human CCD-1106 cells assessed as cell viability after 6 hrs by MTT assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID702318Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular genera
AID1257026Antiproliferative activity against human HaCaT cells2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1278567Cytotoxicity against human HaCaT cells assessed as LDH level at 2 uM incubated for 4 hrs2016European journal of medicinal chemistry, Mar-03, Volume: 1108-Halo-substituted naphtho[2,3-b]thiophene-4,9-diones as redox-active inhibitors of keratinocyte hyperproliferation with reduced membrane-damaging properties.
AID538297Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM after 4 hrs by UV method relative to control2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID1257020Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID85483Antiproliferative activity (AA) against HaCaT keratinocytes.1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids.
AID536637Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis and biological evaluation of novel 10-benzyl-substituted 4,5-dichloro-10H-anthracen-9-ones as inhibitors of keratinocyte hyperproliferation.
AID1363739Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID688878Growth inhibition of human HaCaT cells after 72 hrs by neutral red uptake assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID536639Antioxidant activity assessed as DPPH free radical scavenging activity by spectrophotometry2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis and biological evaluation of novel 10-benzyl-substituted 4,5-dichloro-10H-anthracen-9-ones as inhibitors of keratinocyte hyperproliferation.
AID333175Inhibition of PGE2 production in human HaCaT cells at 5 uM after 24 hrs by RIA2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID1148363Metal chelating activity of the compound assessed as stability constant of metal chelate at 2 to 9 x 10'-5 M using copper1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID1278568Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis2016European journal of medicinal chemistry, Mar-03, Volume: 1108-Halo-substituted naphtho[2,3-b]thiophene-4,9-diones as redox-active inhibitors of keratinocyte hyperproliferation with reduced membrane-damaging properties.
AID85489Induction of Keratinocyte Differentiation in cross-linked envelope assay at 1 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID231071Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID85497Concentration required to inhibit 50% growth of HaCaT cells2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID1181062Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones.
AID1257030Cytotoxicity against human HaCaT cells assessed as cell survival at 10 uM after 48 hrs by MTT assay (Rvb = 95.75 +/- 2.47%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID333173Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation at 5 uM after 24 hrs2004Journal of natural products, Sep, Volume: 67, Issue:9
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1257028Cytotoxicity against human HaCaT cells assessed as cell survival at 0.1 uM after 48 hrs by MTT assay (Rvb = 96.75 +/- 1.77%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID494206Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 1. Synthesis and antiproliferative activity of simple N-unsubstituted 10H-acridin-9-ones against human keratinocyte growth.
AID85614Cytotoxic activity of LDH(mu) release in HaCaT cells was measured after treatment of 2 uM2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID1148365Metal chelating activity of the compound assessed as stability constant of metal chelate at 2 to 9 x 10'-5 M using Zn2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID85494Compound was tested for the induction of HaCaT keratinocyte differentiation at 10 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID85612Compound was measured for lactate dehydrogenase (LDH) release in HaCaT cells after treatment with 2 uM1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
10-omega-phenylalkyl-9(10H)-anthracenones as inhibitors of keratinocyte growth with reduced membrane damaging properties.
AID161309Inhibitory concentration against Prostaglandin G/H synthase; No effect1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID702317Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM after 4 hrs by UV method2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular genera
AID1257023Anti-inflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1148371Metal chelating activity of the compound assessed as stability constant of metal chelate at 2 to 9 x 10'-5 M using Ca2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID379835Prooxidant activity assessed as hydroxyl radical formation at 75 uM measured as malondialdehyde per mmol of deoxyribose by deoxyribose assay1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID688886Cytotoxicity against human HaCaT cells assessed as cell viability after 6 hrs by MTT assay2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.
AID1808023Inhibition of SARS-COV2 main protease using Ac-Abu-Tle-Leu-Gln-AFC as substrate by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID227357Deoxyribose degradation as a measure of hydroxyl-radical generation.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
10-omega-phenylalkyl-9(10H)-anthracenones as inhibitors of keratinocyte growth with reduced membrane damaging properties.
AID1742983Inhibition of SIRT5 (unknown origin)2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID54297Tested for the inhibition of lipid peroxidation in bovine brain phospholipid liposomes1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID233179Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID7197Inhibitory concentration against arachidonic acid 5-lipoxygenation1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID1181063Antihyperproliferative activity against human HaCaT cells assessed as LDH release at 2 umol/L after 4 hrs2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones.
AID1148367Metal chelating activity of the compound assessed as stability constant of metal chelate at 2 to 9 x 10'-5 M using Mn2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID379837Growth inhibition of human HaCaT cells assessed as lactate dehydrogenase release at 2 uM after 4 hrs by UV method1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 2. Antiproliferative and cytotoxic activity of gyrophoric, usnic, and diffractaic acid on human keratinocyte growth.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (927)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990478 (51.56)18.7374
1990's217 (23.41)18.2507
2000's112 (12.08)29.6817
2010's94 (10.14)24.3611
2020's26 (2.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.58 (24.57)
Research Supply Index7.03 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index106.76 (26.88)
Search Engine Supply Index2.51 (0.95)

This Compound (50.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials151 (15.38%)5.53%
Trials0 (0.00%)5.53%
Reviews107 (10.90%)6.00%
Reviews0 (0.00%)6.00%
Case Studies32 (3.26%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (0.20%)0.25%
Observational0 (0.00%)0.25%
Other690 (70.26%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis [NCT03348462]Phase 420 participants (Actual)Interventional2017-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]